PMID- 31669925
OWN - NLM
STAT- MEDLINE
DCOM- 20210125
LR  - 20221207
IS  - 1573-2517 (Electronic)
IS  - 0165-0327 (Linking)
VI  - 261
DP  - 2020 Jan 15
TI  - Do Asian and North American patients with bipolar disorder have similar efficacy, 
      tolerability, and safety profile during clinical trials with atypical 
      antipsychotics?
PG  - 259-270
LID - S0165-0327(19)32048-8 [pii]
LID - 10.1016/j.jad.2019.10.012 [doi]
AB  - BACKGROUND: The approvals of psychotropics for bipolar disorder (BD) are mainly 
      based on randomized, double-blind, placebo-controlled trials (RCTs) from North 
      America. It remains unknown whether approved psychotropics have similar efficacy, 
      tolerability, and safety for Asians with BD. The aim of this systematic review 
      was to compare those differences of psychotropics between Asians and North 
      Americans with BD. METHODS: MEDLINE, EMBASE, and PsycINFO were searched for RCTs 
      studied in two regions. The effect size, remission/response rate, and risk for 
      discontinuation due to adverse events (AEs), weight gain (WG), nervous systems 
      and gastrointestinal AEs were assessed and compared between two regions with 
      Cohen's d or number needed to treat/harm. RESULTS: Eleven studies of 
      aripiprazole, olanzapine, risperidone, and quetiapine in BD were included. 
      Similar efficacy and relatively benign tolerability of atypical antipsychotics 
      (AAPs) between Asians and Americans with BD were observed in most studies. The 
      risk for AAP-related WG was similar between two regions. Asians with mania or 
      bipolar depression were more vulnerable to akathisia/tremor or constipation. 
      Japanese and Chinese with bipolar depression were more sensitive to somnolence 
      and dizziness, respectively. Americans were more likely to have dry mouth, 
      nausea, and vomiting. LIMITATIONS: The number of included psychotropics and 
      papers was small. CONCLUSIONS: Differences in AAP-related efficacy and 
      tolerability were minimal between the two regions, but some AEs appeared to be 
      different. Clinicians should pay attention to these differences to optimize 
      treatment strategies in different races/ethnicities with BD.
CI  - Copyright (c) 2019. Published by Elsevier B.V.
FAU - Bai, Yuanhan
AU  - Bai Y
AD  - Shenzhen Kangning Hospital, Shenzhen, Guangdong, China; Mood and Anxiety Clinic 
      in the Mood Disorders Program, Department of Psychiatry, University Hospitals 
      Cleveland Medical Center, Cleveland, Ohio, USA. Electronic address: 
      baiyuanhan@163.com.
FAU - Chen, Guanjie
AU  - Chen G
AD  - Shenzhen Kangning Hospital, Shenzhen, Guangdong, China.
FAU - Yang, Haichen
AU  - Yang H
AD  - Shenzhen Kangning Hospital, Shenzhen, Guangdong, China.
FAU - Gao, Keming
AU  - Gao K
AD  - Mood and Anxiety Clinic in the Mood Disorders Program, Department of Psychiatry, 
      University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA; Case Western 
      Reserve University School of Medicine, Cleveland, Ohio, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Systematic Review
DEP - 20191011
PL  - Netherlands
TA  - J Affect Disord
JT  - Journal of affective disorders
JID - 7906073
RN  - 0 (Antipsychotic Agents)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
RN  - 82VFR53I78 (Aripiprazole)
RN  - L6UH7ZF8HC (Risperidone)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*therapeutic use
MH  - Aripiprazole/therapeutic use
MH  - Asian People
MH  - Bipolar Disorder/*drug therapy/*ethnology
MH  - Female
MH  - Humans
MH  - North America/ethnology
MH  - Olanzapine/therapeutic use
MH  - Quetiapine Fumarate/therapeutic use
MH  - Risperidone/therapeutic use
MH  - United States
MH  - Weight Gain
OTO - NOTNLM
OT  - Bipolar disorder
OT  - Efficacy
OT  - Ethnicity
OT  - Race
OT  - Safety
OT  - Tolerability
EDAT- 2019/11/02 06:00
MHDA- 2021/01/26 06:00
CRDT- 2019/11/01 06:00
PHST- 2019/08/01 00:00 [received]
PHST- 2019/09/18 00:00 [revised]
PHST- 2019/10/09 00:00 [accepted]
PHST- 2019/11/02 06:00 [pubmed]
PHST- 2021/01/26 06:00 [medline]
PHST- 2019/11/01 06:00 [entrez]
AID - S0165-0327(19)32048-8 [pii]
AID - 10.1016/j.jad.2019.10.012 [doi]
PST - ppublish
SO  - J Affect Disord. 2020 Jan 15;261:259-270. doi: 10.1016/j.jad.2019.10.012. Epub 
      2019 Oct 11.